Oncology

#Francis Crick Institute #Genetics / genomics #Kidney cancer #Oncology

Gene mapping predicts cancer variants with 100% accuracy

Researchers at the Francis Crick Institute have mapped all the possible outcomes of changes to a tumour-suppressing gene called VHL. The VHL map could help clinicians work out which patients are at risk of developing kidney cancer or might respond to certain drugs. It… Read More

#Cancer Research #News

#FDA #Oncology #Prostate cancer #Syncromune

FDA grants Fast Track designation to prostate cancer treatment

Biopharmaceutical company Syncromune has had its lead-candidate for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) granted Fast Track designation by the FDA. Syncromune’s SYNC-T SV-102 therapy is a personalised treatment that comprises of an in situ vaccine via partial oncolysis of a tumour followed by intratumoral infusion of the SV-102 fixed-dose… Read More

#Cancer Research #News #Regulatory

Bladder
#Bladder cancer #CHMP #Genetics / genomics #Janssen #Oncology

CHMP okays first therapy targeting FGFR3 alterations in bladder cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Janssen-Cilag’s Balversa (erdafitinib). It is recommended as a monotherapy to treat adult patients with unresectable or metastatic urothelial carcinoma, harbouring susceptible FGFR3 genetic alterations who have previously received at… Read More

#News #Regulatory

Gut microbiome
#City of Hope #Gut microbiome #Immunotherapy #Oncology #Phase I trial

Gut microbiome changes improve outcomes in kidney cancer

In a Phase I trial, patients with metastatic kidney cancer who took a live biotherapeutic product alongside immunotherapy and enzymatic tyrosine kinase inhibitors experienced improved health outcomes. City of Hope, US, researchers are now in discussions with the global SWOG Cancer Research Network to design a… Read More

#Cancer Research #Editor's Choice #News

#Biotech hubs #Cancer research #Cell Science #Genetics / genomics #Mass spectrometry / NMR #Oncology

DDW Summer issue out now

The DDW Summer issue is out now and looks at where the global biotech hubs are for drug discovery and development, asks how 3D genomics can accelerate personalised medicine, and looks at the technological advances in mass spectrometry. It also includes an exclusive global cancer research guide examining the innovation happening… Read More

#Editor's Choice #News

Medical professional examining mammogram
#Breast cancer #Korea University #Oncology #Treatment resistance

Inhibitor overcomes drug resistance in HER2-positive breast cancer

Korean scientists have found that HVH-2930, an innovative HSP90 inhibitor, demonstrates promising efficacy in inducing cancer cell apoptosis and overcoming treatment resistance in HER2-positive breast cancer. Unlike previous HSP90 inhibitors, the compound circumvents limitations by bypassing heat shock response (HSR) induction. Professor Jae Hong… Read More

#Cancer Research #Editor's Choice #News

MRI of the brain showing glioblastoma
#Brain cancer #Clinical trial #Drug repurposing #HIV #Oncology #University of Plymouth

Clinical trial to repurpose HIV drugs to treat brain tumours

Drugs developed to treat HIV and AIDS are being trialled for the first time in patients with multiple brain tumours. Scientists at the Brain Tumour Research Centre of Excellence at the University of Plymouth are conducting a clinical trial to see whether using anti-retroviral medications, ritonavir… Read More

#Cancer Research #Editor's Choice #News

CAR-T for large B-cell lymphoma
#Allogene Therapeutics #allogeneic cell therapies #Cell therapy #Lymphoma #Oncology #Phase II trial

Phase II trial investigates allogeneic CAR-T for large B-cell lymphoma

Allogene Therapeutics and Foresight Diagnostics have announced the initiation of a Phase II trial evaluating the use of cemacabtagene ansegedleucel (cema-cel) as part of the first line treatment regimen for newly diagnosed large B-cell lymphoma (LBCL) patients who are likely to relapse. The ALPHA3 trial will… Read More

#Cancer Research #News

Cancer cells
#Cancer #Drug discovery #Oncology #Radioligand Therapies (RLTs)

How ready are we for radioligand therapies?  

DDW Editor Reece Armstrong speaks to Jasminka Taleska, Director, RLT HCS Readiness and Policy at Novartis, about the opportunities radioligand therapies (RLTs) represent in treating cancer patients.   RA: What are the potentials of RLTs across cancer?  JT: Cancer is an incredibly complex and heterogeneous disease, and, devastatingly, around 10… Read More

#Cancer Research #Exclusive Content

#AI / data analytics / healthtech / informatics #Anti-inflammatory #Artificial intelligence (AI) #Cancer research #Covid-19 #EpicentRx #Immunology / Virology & Vaccines #Oncology #Polypharmacologic #Precision medicine #Protein binders #Therapeutic targets

New podcast on the significance of drug repurposing

This is the latest episode of the free DDW narrated podcast, titled “Why drug repurposing is so significant for drug discovery” which covers three written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: AI use in repurposing drugs for Covid-19 and RRx-001: Jack… Read More

#News

Vaccine research
#Cancer immunotherapy #Immune response #Immunotherapy #Oncology #University of Turku

Discovery of protein’s role could improve cancer immunotherapies

Researchers at the University of Turku in Finland have discovered that the protein TIMP-1 plays a critical role in the immune system’s defence against cancer. TIMP-1 is produced by dendritic cells, which are responsible for initiating immune responses and boosting the immune system’s ability to recognise… Read More

#Cancer Research #News

microRNA
#Australia #Bowel cancer #Finders University #microRNAs #Oncology

Metformin slows cancer growth using microRNAs, study finds

Australian researchers have analysed how an antidiabetic treatment could help control the growth of tumours, potentially paving the way for the design of better cancer treatments. The new study investigated what happens when metformin, a type 2 diabetes medication, is used to treat colorectal cancer cells,… Read More

#Cancer Research #News

#Biomarkers #Collaboration #Dana-Farber Cancer Institute #OncoHost #Oncology

Companies partner to identify biomarkers for renal cell carcinoma

OncoHost and Dana-Farber Cancer Institute have launched a new study to identify biomarkers for renal cell carcinoma (RCC). Immune-checkpoint inhibitor (ICI) therapy has transformed treatment outcomes for RCC. However, ICIs can also trigger immune-related adverse events and may not benefit all patients. The collaboration… Read More

#Cancer Research #News

#ASCO #Cancer research #Cancer therapeutics #Oncology

New DDW Highlights podcast: 11 June 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluding this week,… Read More

#News

#ASCO #Cancer research #Cancer therapeutics #Oncology

This week in drug discovery (3-7 June) 

News round-up for 3-7 June by DDW Senior Digital Content Editor Diana Spencer. With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluding this week, the headline news has all focused on breakthrough cancer research shared at the event. The top stories:… Read More

#News